CStone’s PD-1 inhibitor CS1003 gets clinical trial approval in China
CStone will initiate a multi-center Phase I clinical trial to assess the safety, tolerability and preliminary anti-tumor activity of CS1003…
CStone will initiate a multi-center Phase I clinical trial to assess the safety, tolerability and preliminary anti-tumor activity of CS1003…
Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by…
A clinical trial testing AstraZeneca’s experimental drug AZD1775, an inhibitor of the cell cycle regulating protein WEE1, in patients with…